A Study of Anti-HIV Monoclonal Antibody KD-247

A minimum of 6 active subjects and 3 placebo subjects for each dose cohort will complete 2
weeks of infusions. A maximum of 27 total subjects will be dosed with KD-247 and up to 9
total will receive placebo. Per cohort subjects randomized to active treatment will receive
iv infusions of KD 247 over 2 hours at each dosing visit. Subjects randomized to placebo
will receive 2-hour iv infusions of saline solution at each dosing visit. Following the
first infusion of KD-247 (or placebo) for each subject in the study, there will be a 24-hour
in-patient observation period before the next subject can be randomized within the study.
Dose escalation will proceed only after safety data through Day 18 for all subjects in the
lower-dose cohort is reviewed.